Androgen Receptor Inhibitor Market Size, ARPI Trends, Pipeline & Forecast 2035

Androgen Receptor Inhibitor Market Size & Forecast 2035

The global androgen receptor inhibitor market was valued at US$8.40 billion in 2025 and is projected to reach US$19.17 billion by 2035, growing at a CAGR of 8.6% during 2026–2035. Growth is being driven by the movement of androgen receptor pathway inhibitors into earlier prostate cancer settings, greater treatment intensification in metastatic castration-sensitive disease, wider use of AR-targeted combinations, and investment in next-generation therapies designed to overcome resistance to enzalutamide, apalutamide and darolutamide.

The strongest commercial opportunity is no longer limited to metastatic castration-resistant prostate cancer. XTANDI is now indicated across CRPC, metastatic castration-sensitive prostate cancer and high-risk biochemical recurrence after definitive local treatment; ERLEADA covers metastatic castration-sensitive and non-metastatic castration-resistant disease; and NUBEQA covers non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer, with or without docetaxel.

The July 31, 2026 FDA approval of Pluvicto in combination with androgen receptor pathway inhibitor therapy for PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer further strengthens the role of ARPI therapy as a backbone on which radioligand treatment can be added rather than a treatment class used in isolation.

Androgen Receptor Inhibitor Market Highlights

• 2025 Market Size: US$8.40 Billion
• 2035 Market Size: US$19.17 Billion
• CAGR, 2026–2035: 8.6%
• Largest Region: North America
• North America Market Share: 42.8% in 2025
• Fastest-Growing Region: Asia-Pacific
• Leading Drug Type: Non-Steroidal Antiandrogens, with 71.3% market share in 2025
• Largest Application: Prostate Cancer, with 78.5% market share in 2025
• Leading Distribution Channel: Hospital Pharmacies, with 52.4% market share in 2025
• Leading End User: Hospitals, with 58.3% market share in 2025
• Key Growth Areas: mCSPC/mHSPC treatment intensification, high-risk biochemical recurrence, PSMA radioligand + ARPI therapy, PARP + androgen-axis combinations, AR degraders, RIPTAC therapies, AR mutation-directed treatment and precision sequencing after ARPI resistance.

The AR Inhibitor Market Is Moving Earlier in the Prostate Cancer Journey

The most important commercial change in androgen receptor inhibition is stage migration. Second-generation AR inhibitors were initially concentrated in advanced or castration-resistant prostate cancer. Their labels now extend across non-metastatic CRPC, metastatic castration-sensitive disease and, in the case of enzalutamide, high-risk biochemical recurrence before radiographically visible metastases develop.

This matters commercially because earlier treatment increases the eligible patient population and can extend treatment duration. It also changes who makes the prescribing decision. The market increasingly involves urologists and multidisciplinary prostate cancer teams alongside medical oncologists, particularly in biochemical recurrence and hormone-sensitive disease.

The EMBARK study illustrates the earlier-treatment opportunity. In men with non-metastatic castration-sensitive prostate cancer and high-risk biochemical recurrence, enzalutamide plus leuprolide reduced the risk of metastasis or death by 58% versus leuprolide alone, with a metastasis-free survival hazard ratio of 0.42. Enzalutamide monotherapy also improved metastasis-free survival, with a hazard ratio of 0.63.

The resulting commercial opportunity is not simply more prescriptions. It is a shift toward longer AR pathway management across multiple prostate cancer states, making treatment persistence, tolerability, reimbursement and sequencing increasingly important to brand competition.

Strategic Takeaways

• The androgen receptor inhibitor market is projected to increase from US$8.40 billion in 2025 to US$19.17 billion by 2035, with second-generation non-steroidal agents driving much of the value expansion.
• Prostate cancer accounts for 78.5% of market revenue, making prostate cancer stage migration and treatment sequencing far more important to market growth than peripheral antiandrogen indications.
• Non-steroidal antiandrogens hold 71.3% of market revenue, supported by enzalutamide, apalutamide and darolutamide and the continued displacement of older antiandrogen approaches in advanced prostate cancer.
• Darolutamide is gaining commercial momentum quickly. NUBEQA sales reached €2.385 billion in 2025, rising 56.6% year over year, while U.S. real-world research published in August 2026 found first-line darolutamide use reached 42% among analyzed ARPI initiations by 2023.
• ARPI therapy is becoming a combination backbone. The 2026 Pluvicto approval adds PSMA-targeted radioligand therapy to ARPI treatment in metastatic androgen-sensitive disease, while PARP combinations increasingly connect AR signaling with genomic selection.
• Resistance is becoming its own investable market. Johnson & Johnson paid US$3.05 billion for Halda Therapeutics and its RIPTAC platform, while Novartis licensed the AR degrader ARV-766 in a transaction carrying US$150 million upfront and up to US$1.01 billion in milestones.
• Loss-of-exclusivity and pricing pressure will increasingly separate volume growth from revenue growth. Astellas reported FY2025 XTANDI sales of ¥960.8 billion but forecasts ¥910.0 billion for FY2026, while Bayer reported U.S. NUBEQA pricing pressure from the Inflation Reduction Act despite strong volume growth.

Where the Revenue Opportunity Sits Across Prostate Cancer States

Metastatic Castration-Sensitive Prostate Cancer Is Becoming the Main Expansion Battlefield

Metastatic castration-sensitive prostate cancer, also referred to as metastatic hormone-sensitive prostate cancer, has become one of the most competitive AR inhibitor settings.

Apalutamide, enzalutamide and darolutamide can all participate in hormone-sensitive metastatic disease, but their commercial positioning differs according to clinical evidence, use of chemotherapy, physician familiarity, safety profile and combination strategy.

Darolutamide's position changed materially in June 2025 when FDA expanded NUBEQA to mCSPC without requiring docetaxel. ARANOTE enrolled 669 patients and showed a radiographic progression-free survival hazard ratio of 0.54 versus placebo plus androgen deprivation therapy. Median rPFS was not reached with darolutamide and was 25 months in the control arm.

The approval widens the addressable population beyond patients selected for chemotherapy-containing triplet treatment and places darolutamide in more direct competition with apalutamide and enzalutamide.

Real-world prescribing supports this competitive shift. A 2026 U.S. study examining 1.1 million prostate cancer patients found that first-line darolutamide increased to 42% of analyzed ARPI initiations in 2023, surpassing enzalutamide among first-line users, although enzalutamide remained the most frequently used ARPI overall.

Non-Metastatic CRPC Remains an Established Three-Brand Market

Non-metastatic castration-resistant prostate cancer established the competitive framework for apalutamide, enzalutamide and darolutamide.

ERLEADA and NUBEQA maintain specific nmCRPC indications, while XTANDI's broader CRPC indication covers the castration-resistant disease spectrum.

The market is mature relative to mCSPC, which means future commercial differentiation depends less on simply demonstrating metastasis-free survival benefit and more on physician preference, adverse-event profiles, drug interactions, persistence and payer positioning.

The same 2026 real-world study showing rapid darolutamide uptake indicates that prescribing within the second-generation ARPI class can shift even after incumbent products have established strong clinical positions.

High-Risk Biochemical Recurrence Creates an Earlier Enzalutamide Market

High-risk biochemical recurrence is commercially distinct because patients have rising PSA after definitive therapy but do not yet have radiographically metastatic disease.

XTANDI currently has the broadest U.S. AR inhibitor label in this setting. FDA approved enzalutamide for non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence in November 2023. EMBARK enrolled 1,068 patients and demonstrated statistically significant metastasis-free survival improvement with both enzalutamide plus leuprolide and enzalutamide monotherapy.

The label expands AR inhibition into a population that historically faced a choice between surveillance and androgen deprivation strategies. It also introduces the commercial concept of treatment suspension and reinitiation according to PSA response, creating a different duration and adherence model from uninterrupted therapy in metastatic disease.

For competitors, high-risk biochemical recurrence remains an important white-space opportunity because enzalutamide currently holds a differentiated label position.

mCRPC Is Becoming a Sequencing and Resistance Market

Metastatic castration-resistant prostate cancer remains the disease setting with the greatest mechanistic complexity.

Many patients have already received an ARPI before reaching later-line mCRPC. This reduces the value of simply introducing another conventional receptor antagonist and increases demand for therapies capable of overcoming AR mutations, AR amplification, splice variants and other mechanisms of androgen pathway resistance.

The commercial question has therefore shifted from “Can the androgen receptor be inhibited?” to “Can AR-driven disease still be controlled after established ARPI exposure?”

This is the opportunity being pursued by targeted protein degraders, RIPTAC molecules and combination therapies that attack both the androgen receptor pathway and complementary mechanisms.

ARPI Therapy Is Becoming a Backbone for Other High-Value Oncology Platforms

PSMA Radioligand Therapy + ARPI Creates a New Combination Category

The most important 2026 development for the ARPI market is the FDA approval of Pluvicto plus androgen receptor pathway inhibitor therapy in PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.

PSMAddition randomized patients to Pluvicto plus ARPI or ARPI alone. The combination reduced the risk of radiographic progression or death, with an rPFS hazard ratio of 0.72.

Commercially, this does not replace ARPI treatment. It strengthens it.

An ARPI remains part of the approved regimen, meaning radioligand expansion can increase rather than diminish the strategic importance of AR pathway therapy. It also creates a new procurement ecosystem connecting oral oncology drugs with PSMA PET testing, nuclear medicine infrastructure and radiopharmaceutical delivery.

PARP + Androgen-Axis Therapy Is Expanding Biomarker-Selected Demand

The androgen pathway is also becoming part of precision treatment based on homologous recombination repair alterations.

In December 2025, FDA approved AKEEGA—niraparib plus abiraterone acetate—with prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer. In the BRCA2-mutated subgroup of AMPLITUDE, the rPFS hazard ratio was 0.46 compared with abiraterone acetate plus prednisone alone.

AKEEGA also has a BRCA-mutated mCRPC indication. The fixed-dose product therefore links androgen synthesis inhibition with PARP inhibition across two metastatic disease settings.

For market buyers, the commercial implication is greater demand for genomic testing and more treatment decisions driven by BRCA and HRR status rather than disease stage alone.

Enzalutamide also participates in biomarker-selected combination treatment through TALZENNA plus XTANDI in HRR-mutated mCRPC, reinforcing the broader shift from single-pathway AR therapy toward genomic combination strategies.

Product Competition: XTANDI Leads in Scale, NUBEQA Leads in Growth

XTANDI: The Largest Established AR Inhibitor Franchise

Astellas reported ¥960.8 billion in FY2025 XTANDI sales, up 5.3% from ¥912.3 billion in FY2024. The product remains one of the largest commercial prostate cancer franchises and has the broadest current U.S. disease-state coverage among the three major second-generation receptor antagonists.

XTANDI's commercial strength comes from its long market presence and indications across CRPC, mCSPC and high-risk biochemical recurrence.

The challenge is franchise maturity. Astellas forecasts ¥910.0 billion in FY2026 XTANDI sales, down 5.3% from FY2025, making lifecycle management and replacement pipeline assets increasingly important.

ERLEADA: Strong Growth in a Focused Prostate Cancer Franchise

Johnson & Johnson reported US$3.574 billion in worldwide ERLEADA sales in 2025, increasing 19.2% from US$2.999 billion in 2024. U.S. sales reached US$1.453 billion and international sales US$2.121 billion.

ERLEADA is approved for metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer.

Johnson & Johnson's competitive strategy extends beyond apalutamide. The company has built a broader prostate cancer portfolio spanning AR inhibition, androgen synthesis/PARP combinations and, following the Halda transaction, next-generation resistance-focused therapeutics.

NUBEQA: Fastest Current Brand Growth

NUBEQA produced one of the strongest growth rates among major prostate cancer medicines in 2025.

Bayer reported €2.385 billion in NUBEQA sales, up 56.6% from €1.523 billion in 2024. Currency- and portfolio-adjusted growth reached 62.4%, with strong volume expansion across regions.

The June 2025 U.S. approval for darolutamide with ADT in mCSPC without mandatory docetaxel materially broadened the product's competitive reach. Europe followed with marketing authorization in July 2025 and China approved the indication in February 2026.

Bayer's annual report lists NUBEQA active-ingredient protection extending into the 2030s across major markets, giving the brand a different lifecycle profile from older AR inhibitor franchises.

Resistance to Current AR Inhibitors Is Creating the Next Premium Market

Resistance remains the central innovation problem in advanced prostate cancer.

Tumors can remain dependent on AR signaling while developing receptor mutations, amplification or splice variants that reduce the effectiveness of established antagonists. Other tumors become less dependent on AR signaling through lineage plasticity and neuroendocrine transformation.

This makes standard “next-generation antiandrogen” development less attractive unless the drug can address a specific resistance mechanism.

ARV-766: Targeted Protein Degradation

Novartis acquired global development and commercialization rights to ARV-766, a second-generation PROTAC androgen receptor degrader, in April 2024.

Arvinas received US$150 million upfront and remains eligible for up to US$1.01 billion in development, regulatory and commercial milestones, plus royalties. The agreement also transferred an AR-V7 program to Novartis.

ARV-766 is designed to degrade wild-type AR and clinically relevant ligand-binding-domain mutants rather than simply block ligand binding.

Early Phase I/II results reported a PSA50 response in 43% of patients with AR ligand-binding-domain mutations, supporting continued development in heavily pretreated mCRPC.

This platform directly addresses one of the highest-value gaps in the market: patients whose cancers remain AR-driven after previous ARPI treatment.

HLD-0915: RIPTAC Therapy Attracts a US$3.05 Billion Acquisition

Johnson & Johnson completed its acquisition of Halda Therapeutics in December 2025 for US$3.05 billion in cash.

The transaction added HLD-0915, a once-daily oral prostate cancer candidate built on Halda's Regulated Induced Proximity Targeting Chimera, or RIPTAC, platform. J&J states that the molecule is intended to overcome key prostate cancer resistance pathways through targeted tumor-cell killing.

The acquisition is one of the clearest commercial signals that the industry sees value beyond conventional AR antagonism.

Rather than competing head-to-head with enzalutamide, apalutamide or darolutamide in untreated patients, HLD-0915 is aimed at biologically resistant disease where current ARPI options are less effective.

Androgen Receptor Inhibitor Market Segment Analysis

By Drug Type: Non-Steroidal Antiandrogens Hold 71.3% of Market Revenue

Non-steroidal antiandrogens accounted for 71.3% of global androgen receptor inhibitor market revenue in 2025, making them the largest drug-type segment.

The segment includes established first-generation drugs and higher-value second-generation receptor inhibitors such as enzalutamide, apalutamide and darolutamide. The commercial center of gravity has shifted decisively toward newer agents because they are used across multiple prostate cancer stages and generate multibillion-dollar annual brand revenues.

The growth profile is particularly strong for darolutamide. NUBEQA sales increased 56.6% in 2025, compared with 19.2% growth for ERLEADA and 5.3% for XTANDI in their companies' reported currencies. These figures do not represent equivalent market-share calculations, but they clearly show differing brand momentum.

Androgen Synthesis Inhibitors Remain Important but Face Generic Pressure

The DMI market scope also includes androgen synthesis inhibitors, which suppress production of androgenic hormones rather than directly antagonizing the receptor.

Abiraterone remains the most commercially important example and continues to have strategic relevance because it serves as the hormonal backbone for biomarker-directed combinations such as AKEEGA.

Its commercial profile differs from newer receptor antagonists because widespread generic availability lowers drug-acquisition cost. Future value within this segment is therefore increasingly tied to fixed-dose combinations, genomic selection and treatment intensification, not premium pricing for abiraterone monotherapy.

By Application: Prostate Cancer Accounts for 78.5% of the Market

Prostate cancer generated 78.5% of androgen receptor inhibitor revenue in 2025, confirming that the market should be analyzed primarily through prostate cancer treatment states rather than as a broad endocrine-therapy category.

The scale of the addressable population remains substantial. IARC recorded 1,546,112 new prostate cancer cases and 419,849 deaths worldwide in 2024. Five-year prevalence reached 5.18 million men.

The prostate cancer segment is also becoming more valuable per patient because ARPI therapy is moving into hormone-sensitive disease, high-risk biochemical recurrence and multi-agent regimens.

Other Applications Remain Smaller and More Experimental

AR biology has generated interest beyond prostate cancer, including androgen receptor-expressing breast cancer and other hormone-responsive disorders. However, these uses remain substantially smaller than prostate cancer in current commercial revenue.

For investors, breast cancer and other solid-tumor programs should therefore be evaluated as pipeline upside rather than the primary basis of the 2026–2035 market forecast.

By Distribution Channel: Hospital Pharmacies Lead, Online Specialty Access Is Growing Faster

Hospital pharmacies accounted for 52.4% of androgen receptor inhibitor revenue in 2025, followed by retail pharmacies at 30.1%.

Hospital pharmacy leadership reflects the fact that treatment is initiated within oncology and urology pathways and increasingly forms part of complex regimens involving ADT, chemotherapy, PARP inhibitors or radioligand therapy.

Online pharmacies held 17.5% of revenue in 2025 but represent the fastest-growing distribution channel in the cited market benchmark, supported by specialty-pharmacy delivery and long-term oral treatment.

The shift toward earlier-stage oral treatment can strengthen direct-to-patient specialty distribution because many patients remain on AR inhibitors outside the infusion-center setting.

By End User: Hospitals Hold 58.3%, but Specialty Clinics Are Expanding

Hospitals represented 58.3% of market revenue in 2025, while specialty clinics held 30.4%.

Hospitals remain central for patients receiving multimodal treatment, advanced imaging, chemotherapy, radioligand therapy or genomic testing.

Specialty urology and oncology clinics are becoming more commercially important as AR inhibitors move earlier into hormone-sensitive disease and biochemical recurrence. These settings can initiate and monitor long-duration oral therapy while referring patients to tertiary hospitals when radioligand, chemotherapy or complex salvage treatment becomes necessary.

Regional Market Analysis

North America: 42.8% Revenue Share and the Highest Commercial Intensity

North America accounted for 42.8% of global androgen receptor inhibitor revenue in 2025, making it the largest regional market.

The region's leadership reflects rapid uptake of second-generation AR inhibitors, high specialty-drug expenditure, broad access to prostate cancer imaging and genomic testing and early FDA approvals across multiple disease states.

Northern America represented 19.9% of worldwide prostate cancer incidence in 2024, with 306,913 cases, but held 24.3% of global five-year prevalent cases. The region's AR inhibitor revenue share is therefore considerably higher than its incidence share, consistent with higher treatment expenditure per eligible patient.

The United States continues to drive innovation. NUBEQA received its expanded mCSPC indication in June 2025, AKEEGA entered BRCA2-mutated mCSPC in December 2025 and Pluvicto plus ARPI gained an earlier metastatic prostate cancer indication in July 2026.

Europe: 27.4% AR Inhibitor Revenue Share and the World's Largest Prostate Cancer Burden

Europe accounted for 27.4% of androgen receptor inhibitor market revenue in 2025.

Europe simultaneously carries the world's largest regional prostate cancer incidence burden. IARC recorded 462,099 new cases in 2024, representing 29.9% of worldwide incidence, while five-year prevalence reached 1.87 million men, or 36.1% of the global total.

This combination of high incidence, extensive urology infrastructure and broad access to modern hormonal therapies supports sustained demand across Germany, France, Italy, Spain, the UK and Nordic markets.

Pricing and health-technology assessment remain more restrictive than in the United States, while generic access to older androgen-axis therapies places a greater burden on premium products to show clinically meaningful incremental benefit.

Asia-Pacific: 21.3% Revenue Share and the Fastest Growth

Asia-Pacific accounted for 21.3% of market revenue in 2025 and is the fastest-growing regional androgen receptor inhibitor market, with the current benchmark projecting 10.2% annual growth through 2034.

Asia recorded 426,203 prostate cancer cases in 2024, representing 27.6% of worldwide incidence, and 132,545 deaths, representing 31.6% of global prostate cancer mortality.

The difference between Asia's disease-burden share and its current AR inhibitor revenue share leaves meaningful room for commercial expansion.

China, Japan, South Korea and Australia are expected to lead premium therapy adoption, while India and Southeast Asia offer larger long-term volume opportunities as diagnosis, insurance coverage and access to advanced hormonal therapy improve.

China's importance is already increasing. The NMPA approved NUBEQA plus ADT for mHSPC in February 2026, widening access to second-generation AR inhibition in one of the world's largest oncology markets.

Latin America: Strong Disease Burden but Wider Access Gaps

Latin America and the Caribbean accounted for 215,448 prostate cancer cases in 2024, representing 13.9% of global incidence, and 63,058 deaths, representing 15.0% of mortality.

The AR inhibitor commercial market remains smaller than the disease burden would suggest. Brazil and Mexico offer the strongest regional specialty-pharmaceutical opportunity, while affordability and public-sector reimbursement remain major determinants of access.

Generic bicalutamide and abiraterone retain greater importance in cost-sensitive settings, while newer AR inhibitors are concentrated in private hospitals and high-complexity cancer centers.

This creates a dual market: premium second-generation ARPI growth in major urban cancer networks and greater volume demand for lower-cost androgen-axis therapies across public health systems.

Middle East and Africa: Prostate Cancer Mortality Highlights the Access Opportunity

Africa recorded 111,533 new prostate cancer cases and 61,796 deaths in 2024, representing 7.2% of incidence but 14.7% of global prostate cancer mortality.

The mortality burden highlights limitations in screening, stage at diagnosis and access to advanced treatment.

High-income Gulf markets offer growing demand for second-generation AR inhibitors, precision diagnostics and multidisciplinary prostate cancer treatment. Across broader Africa, the larger near-term commercial opportunity remains reliable access to effective hormonal treatment and oncology infrastructure rather than rapid penetration of every premium combination.

Country-Level Commercial Priorities

United States

The United States recorded 278,556 new prostate cancer cases in IARC's 2024 dataset, making prostate cancer the most frequently diagnosed cancer among U.S. men in that dataset. Five-year prevalence reached 1.14 million men.

The U.S. is also the most dynamic market for AR pathway combinations. Patients can access enzalutamide, apalutamide and darolutamide across multiple disease states alongside PARP combinations, radioligand treatment and genomic testing.

The approval of Pluvicto plus ARPI in July 2026 strengthens the need for coordinated treatment between urology, medical oncology and nuclear medicine.

China

China recorded 163,941 new prostate cancer cases in 2024, making prostate cancer the fifth most frequently diagnosed cancer among Chinese men.

The country represents one of the clearest long-term AR inhibitor growth opportunities because its current market penetration remains below North American levels while diagnosis and access to modern prostate cancer treatment continue to expand.

The February 2026 NUBEQA mHSPC approval adds another major second-generation AR inhibitor option to the Chinese market.

Germany

Germany recorded 58,715 new prostate cancer cases in 2024, making prostate cancer the most frequently diagnosed malignancy among German men. Five-year prevalence reached 259,980 men.

Germany's high prostate cancer burden and established reimbursement system support substantial demand for second-generation hormonal treatment.

Commercial success, however, depends heavily on demonstrated additional benefit and payer assessment, particularly as lower-cost older hormonal therapies remain available.

Japan

Japan remains strategically important because of its aging male population, extensive prostate cancer treatment infrastructure and strong participation by domestic pharmaceutical companies in the androgen-axis market.

Astellas is the commercial partner behind XTANDI and reported continued global sales growth in FY2025. Japan also participates in the expanding adoption of next-generation prostate cancer combinations and biomarker-selected treatment.

India

India represents a long-term volume opportunity rather than the highest current revenue-per-patient market.

Expansion is being supported by increasing cancer-center capacity, local generic manufacturing and greater use of oral oncology therapies. Generic androgen-axis products remain important because affordability strongly influences treatment access.

As diagnosis shifts toward earlier stages and private oncology networks expand, second-generation AR inhibitors can gain share among patients who currently receive older hormonal therapies.

Patent, Generic and Pricing Pressure Are Becoming Core Buying Issues

Androgen receptor inhibition is entering a period in which clinical demand can rise even while revenue growth becomes harder to sustain for mature brands.

XTANDI illustrates the transition. FY2025 sales reached ¥960.8 billion, but Astellas forecasts a decline to ¥910.0 billion in FY2026.

This means buyers should distinguish between:

Market volume growth, driven by more patients receiving ARPI therapy earlier.

Brand revenue growth, driven by indication expansion, differentiated efficacy, patent protection and pricing.

Class revenue growth, which can be reduced by generic substitution even if total prescriptions increase.

NUBEQA currently benefits from strong growth and a younger lifecycle. Bayer reported that U.S. pricing was already negatively affected by the Inflation Reduction Act in 2025, even while product volumes rose sharply.

The long-term winners will therefore need either durable intellectual-property protection, novel indications, compelling combination data or a mechanism capable of treating ARPI-resistant disease.

Pipeline and Deal-Making Priorities Through 2035

AR Degraders

Protein degradation is one of the strongest mechanistic opportunities because it removes AR protein rather than only blocking its activation.

ARV-766 is the most commercially visible example after Novartis acquired worldwide development rights. The US$150 million upfront payment and potential US$1.01 billion milestone package demonstrate the value placed on next-generation AR degradation.

The opportunity is particularly relevant to tumors with ligand-binding-domain mutations that can retain signaling despite conventional receptor antagonism.

RIPTACs

Johnson & Johnson's US$3.05 billion Halda acquisition gives RIPTAC technology a major pharmaceutical sponsor.

HLD-0915 is intended to exploit prostate cancer-specific biology and kill tumor cells through induced protein proximity, creating a mechanism that could remain active when conventional AR antagonists no longer control disease.

Radioligand + ARPI Therapy

The Pluvicto approval establishes ARPI therapy as a partner to PSMA-targeted radioligand treatment in metastatic androgen-sensitive disease.

This creates commercial opportunity not only for AR inhibitor manufacturers but also for PSMA imaging, nuclear medicine networks and treatment centers capable of delivering lutetium-177 therapy.

PARP + Androgen Pathway Therapy

The 2025 AKEEGA approval in BRCA2-mutated mCSPC pushes genomic testing earlier and increases the commercial value of linking androgen suppression with DNA-repair targeting.

Future market growth will increasingly depend on identifying which biological subgroups benefit sufficiently from treatment intensification to justify additional toxicity and cost.

Market Scope

Recent Developments Reshaping the Androgen Receptor Inhibitor Market

July 2026 – Pluvicto + ARPI Approved in Earlier Metastatic Prostate Cancer

FDA approved Pluvicto with androgen receptor pathway inhibitor therapy for adults with PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. PSMAddition showed an rPFS hazard ratio of 0.72 versus ARPI therapy alone.

June 2026 – Real-World ARPI Data Show Rapid Darolutamide Adoption

A U.S. real-world study published in 2026 found that first-line darolutamide reached 42% of ARPI initiation in 2023 among the analyzed cohort and surpassed enzalutamide for first-line selection, while enzalutamide retained the largest overall utilization.

February 2026 – NUBEQA mHSPC Expansion Reaches China

China's NMPA approved darolutamide with ADT for metastatic hormone-sensitive prostate cancer, extending the 2025 U.S. and European label expansion into another major oncology market.

December 2025 – Johnson & Johnson Completes US$3.05 Billion Halda Acquisition

The acquisition added HLD-0915 and the RIPTAC platform to J&J's prostate cancer pipeline, strengthening its strategy for ARPI-resistant disease.

December 2025 – FDA Approves AKEEGA in BRCA2-Mutated mCSPC

FDA expanded niraparib plus abiraterone acetate with prednisone into BRCA2-mutated metastatic castration-sensitive disease. The BRCA2 subgroup showed an rPFS hazard ratio of 0.46.

June 2025 – Darolutamide Gains mCSPC Approval Without Mandatory Docetaxel

FDA approved NUBEQA for mCSPC based on ARANOTE, where darolutamide reduced radiographic progression or death risk by 46% compared with placebo plus ADT.

Competitive Landscape

Astellas Pharma and Pfizer

Astellas and Pfizer remain central to the market through XTANDI (enzalutamide).

The product's competitive advantage is indication breadth and entrenched prescribing. It spans CRPC, metastatic castration-sensitive prostate cancer and non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.

The commercial challenge is lifecycle maturity. Astellas' FY2026 sales forecast indicates pressure on a franchise that still generated ¥960.8 billion in FY2025.

Johnson & Johnson

Johnson & Johnson has built one of the broadest prostate cancer strategies through ERLEADA, AKEEGA and HLD-0915.

ERLEADA generated US$3.574 billion in 2025 sales, while AKEEGA creates a BRCA-selected androgen synthesis/PARP platform and Halda adds a resistance-focused future pipeline.

This reduces J&J's dependence on a single AR inhibitor mechanism.

Bayer and Orion

Bayer and Orion compete through NUBEQA (darolutamide).

The product's commercial momentum is supported by rapid revenue growth and mCSPC expansion without mandatory chemotherapy. NUBEQA generated €2.385 billion in 2025, rising 56.6%.

Its competitive position through 2035 will depend on continued uptake in hormone-sensitive disease and its ability to maintain differentiation as second-generation ARPI prescribing becomes more crowded.

Novartis

Novartis occupies an increasingly strategic position even though it does not currently market one of the three dominant second-generation AR antagonists.

The company licensed ARV-766 and the AR-V7 program from Arvinas and now has a direct route into next-generation AR degradation.

Its Pluvicto franchise also now requires combination with ARPI therapy in the newly approved mAPMN/S indication, giving Novartis commercial exposure to the ARPI ecosystem from the radioligand side.

Generic Manufacturers

Generic manufacturers including Dr. Reddy's and other global oral oncology suppliers remain important in older antiandrogens and androgen synthesis inhibition.

Their competitive strength is affordability rather than novel clinical differentiation. As mature branded agents lose exclusivity, generic companies can become increasingly influential in Europe, Asia-Pacific, Latin America and other cost-sensitive markets.

Buyer and Investor Evaluation Priorities

• Disease-state coverage should be evaluated first. A drug limited to late-line mCRPC has a very different commercial opportunity from an ARPI approved in hormone-sensitive metastatic disease or biochemical recurrence.

• Combination compatibility is becoming essential. AR inhibitors increasingly need to work alongside ADT, chemotherapy, PARP inhibition or radioligand therapy rather than only as monotherapy.

• Resistance biology determines pipeline value. Assets that degrade AR, address ligand-binding mutations or exploit alternative prostate cancer vulnerabilities have a stronger differentiation case than another conventional receptor blocker.

• Treatment duration affects revenue and patient burden. Earlier treatment can increase duration but also exposes patients to adverse effects for longer periods, increasing scrutiny of fatigue, falls, fractures, cardiovascular risk and drug interactions.

• Patent position must be separated from clinical position. An established drug can continue to lead prescribing while losing pricing power.

• Geographic pricing strategy matters. North America generates a disproportionate share of market revenue, whereas Asia-Pacific offers faster volume expansion and greater long-term patient opportunity.

• Genomic and PSMA testing are becoming part of ARPI economics. BRCA-directed combinations and PSMA radioligand regimens mean treatment choice increasingly depends on diagnostics that sit outside the AR inhibitor prescription itself.